Showing 4421-4430 of 5627 results for "".
- Gyroscope Therapeutics Postpones Initial Public Offeringhttps://modernod.com/news/gyroscope-therapeutics-postpones-initial-public-offering/2479176/Gyroscope Therapeutics announced it has postponed plans for its initial public offering. “In light of market conditions, we have decided to postpone our planned initial public offering,” Khurem Farooq, Chief Executive Officer, said in a company news release. “Based on the
- Ceyeber Announces Advisory Board of World-Renowned Ophthalmologistshttps://modernod.com/news/ceyeber-announces-advisory-board-of-world-renowned-ophthalmologists/2479167/Ceyeber, the developer of implantable intraocular lens technology designed for medical applications and augmented reality, has created a Medical Advisory Board consisting of top ophthalmologists. Ceyeber’s founder and CEO, Robert E. Grant, said, “
- Oculis Announces Financing to Advance Topical Therapies for Posterior and Anterior Segmentshttps://modernod.com/news/oculis-announces-financing-to-advance-therapies-for-anterior-segment/2479162/Oculis announced that it has closed an oversubscribed $57 million Series C financing. Proceeds from this financing will accelerate Oculis’ strategy with the aim of delivering key goals in the near-term to drive shareholder value and bring transformative therapies to patients. The
- jCyte Identifies Predictive Biomarker for jCell Therapy in Largest Phase 3 Study for Retinitis Pigmentosahttps://modernod.com/news/jcyte-identifies-predictive-biomarker-for-jcell-therapy-in-largest-phase-3-study-for-retinitis-pigmentosa/2479157/jCyte announced presentations at the Association for Research in Vision and Ophthalmology (ARVO) 2021 Annual Meeting, identifying a predictive biomarker for the upcoming phase 3 study for jCell therapy in retinitis pigmentosa. A detailed analysis by the Cleveland Clinic Cole Eye Institute
- Novartis: Phase 3 Beovu Data Show Potential for Fluid Resolution in More DME Patients With Fewer Injections Versus Aflibercepthttps://modernod.com/news/novartis-phase-3-beovu-data-show-potential-for-fluid-resolution-in-more-dme-patients-with-fewer-injections-versus-aflibercept/2479150/Novartis announced positive 1-year results of the phase III KESTREL and KITE studies, evaluating the efficacy and safety of Beovu (brolucizumab-dbll) 6 mg in diabetic macular edema (DME). Both studies met their primary endpoints of noninferiority in change in best corrected visual acuity (
- Johnson & Johnson Vision Presents New Myopia, Cataract, Refractive, and Meibomian Gland Dysfunction Data at ARVO 2021https://modernod.com/news/johnson-johnson-vision-presents-new-myopia-cataract-refractive-and-meibomian-gland-dysfunction-data-at-arvo-2021/2479152/Johnson & Johnson Vision will present nearly 30 posters and papers of research data on myopia, IOL, phacoemulsification, refractive, and meibomian gland dysfunction at the Association for Research in Vision and Ophthalmology (ARVO) 2021 Annual Meeting. This year’s premier vision research meet
- The Countess of Wessex Praises Work of Sight-Saving Charity Orbis During Pandemichttps://modernod.com/news/the-countess-of-wessex-praises-work-of-sight-saving-charity-orbis-during-pandemic/2479147/On April 28, 2021, Her Royal Highness The Countess of Wessex spoke in support of international eye care charity Orbis, at a virtual event to discuss delivering eye care to those most in need during the COVID-19 outbreak.
- Oxurion NV Presenting Scientific Data at ARVO 2021 Annual Meetinghttps://modernod.com/news/oxurion-nv-presenting-scientific-data-at-arvo-2021-annual-meeting/2479144/Oxurion NV is announcing the presentation of novel scientific data at the upcoming Association for Research in Vision and Ophthalmology (ARVO) 2021 Annual Meeting which is held on May 1-7, 2021. The details of the presentation are as follows: Title: The Mouse Sodium Iodate Mo
- Alcon to Acquire US Commercialization Rights to Glaucoma Eye Drop Simbrinzahttps://modernod.com/news/alcon-to-acquire-us-commercialization-rights-to-ophthalmic-eye-drop-simbrinza/2479138/Alcon announced it has signed an agreement to acquire exclusive U.S. commercialization rights to Simbrinza (brinzolamide/brimonidine tartrate ophthalmic suspension) 1%/0.2% from Novartis. Under terms of the deal, Alcon will pay $355 million at closing, which is expected to occur in the sec
- Adverum Biotechnologies Reports a Adverse Reaction of Hypotony in the INFINITY Trial Evaluating ADVM-022 in Patients With DMEhttps://modernod.com/news/adverum-biotechnologies-reports-a-adverse-reaction-of-hypotony-in-the-infinity-trial-evaluating-advm-022-in-patients-with-dme/2479135/Adverum Biotechnologies announced a Suspected Unexpected Serious Adverse Reaction (SUSAR) of hypotony (clinically-relevant decrease in ocular pressure) in its INFINITY clinical trial evaluating ADVM-022 gene therapy for the treatment of diabetic macular edema (DME). This event occurr